StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Interpace Biosciences's ebitda for the twelve months ending Jun 30, 2026 was $4.64M, down 23.9% year over year. For fiscal 2025 it was $4.51M, down 46.4% from the year before. The highest annual figure on record is $8.41M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.51M-46.4%
FY2024Dec 31, 2024$8.41M+68.8%
FY2023Dec 31, 2023$4.98M–
FY2022Dec 31, 2022-$1.06M–
FY2021Dec 31, 2021-$962.00K–
FY2020Dec 31, 2020-$20.57M–
FY2019Dec 31, 2019-$21.91M–
FY2018Dec 31, 2018-$8.83M–
FY2017Dec 31, 2017-$2.60M–
FY2016Dec 31, 2016-$1.96M–
FY2015Dec 31, 2015-$35.38M–
FY2014Dec 31, 2014-$15.44M–
FY2013Dec 31, 2013-$12.00K–
FY2012Dec 31, 2012-$23.20M–
FY2011Dec 31, 2011-$1.66M–
FY2010Dec 31, 2010-$5.07M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$448.00K–
Q1 FY2026Mar 31, 2026$1.24M-35.5%
Q4 FY2025Dec 31, 2025$1.70M-21.4%
Q3 FY2025Sep 30, 2025$1.26M-47.4%
Q2 FY2025Jun 30, 2025-$367.00K-113.6%
Q1 FY2025Mar 31, 2025$1.92M+65.0%
Q4 FY2024Dec 31, 2024$2.16M+38.0%
Q3 FY2024Sep 30, 2024$2.39M+266.0%
Q2 FY2024Jun 30, 2024$2.70M+71.5%
Q1 FY2024Mar 31, 2024$1.17M-2.3%
Q4 FY2023Dec 31, 2023$1.56M+282.8%
Q3 FY2023Sep 30, 2023$652.00K–
Q2 FY2023Jun 30, 2023$1.57M–
Q1 FY2023Mar 31, 2023$1.19M–
Q4 FY2022Dec 31, 2022$408.00K–
Q3 FY2022Sep 30, 2022-$145.00K–
Q2 FY2022Jun 30, 2022-$1.12M–
Q1 FY2022Mar 31, 2022-$196.00K–
Q4 FY2021Dec 31, 2021-$328.00K–
Q3 FY2021Sep 30, 2021-$418.00K–
Q2 FY2021Jun 30, 2021-$1.50M–
Q1 FY2021Mar 31, 2021-$2.28M–
Q4 FY2020Dec 31, 2020-$6.54M–
Q3 FY2020Sep 30, 2020-$4.61M–
Q2 FY2020Jun 30, 2020-$4.38M–
Q1 FY2020Mar 31, 2020-$5.03M–
Q4 FY2019Dec 31, 2019-$9.41M–
Q3 FY2019Sep 30, 2019-$5.89M–
Q2 FY2019Jun 30, 2019-$4.39M–
Q1 FY2019Mar 31, 2019-$2.23M–
Q4 FY2018Dec 31, 2018-$3.80M–
Q3 FY2018Sep 30, 2018-$1.60M–
Q2 FY2018Jun 30, 2018-$1.04M–
Q1 FY2018Mar 31, 2018-$2.39M-151.2%
Q4 FY2017Dec 31, 2017-$2.42M-131.3%
Q3 FY2017Sep 30, 2017-$2.22M–
Q2 FY2017Jun 30, 2017-$2.63M–
Q1 FY2017Mar 31, 2017$4.67M–
Q4 FY2016Dec 31, 2016$7.73M–
Q3 FY2016Sep 30, 2016-$5.39M–

More Interpace Biosciences figures

See a number that looks wrong?